Cost-effectiveness of Canakinumab for Prevention of Recurrent Cardiovascular Events | Zendy

T S G Sehested | Zendy; Jenny Bjerre | Zendy; Seul Ku | Zendy; Andrew Y. Chang | Zendy; Alison Jahansouz | Zendy; Douglas K Owens | Zendy; Mark A. Hlatky | Zendy; Jeremy D. GoldhaberFiebert | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Cost-effectiveness of Canakinumab for Prevention of Recurrent Cardiovascular Events

Author(s) -

T S G Sehested,

Jenny Bjerre,

Seul Ku,

Andrew Y. Chang,

Alison Jahansouz,

Douglas K Owens,

Mark A. Hlatky,

Jeremy D. GoldhaberFiebert

Publication year - 2019

Publication title -

jama cardiology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 6.108

H-Index - 63

eISSN - 2380-6591

pISSN - 2380-6583

DOI - 10.1001/jamacardio.2018.4566

Subject(s) - medicine , canakinumab , quality adjusted life year , cost effectiveness , disease , anakinra , risk analysis (engineering)

In the Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS) trial, the anti-inflammatory monoclonal antibody canakinumab significantly reduced the risk of recurrent cardiovascular events in patients with previous myocardial infarction (MI) and high-sensitivity C-reactive protein (hs-CRP) levels of 2 mg/L or greater.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research